Highlights Vera Therapeutics, Inc.

Equities

VERA

US92337R1014

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
41.38 ^USD	+4.36%		+5.75%	+169.05%

Apr. 11	North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge	DJ
Apr. 10	Vera Therapeutics Shares Rise 9.9% After Alpine Acquisition	DJ

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Vera Therapeutics Shares Rise 9.9% After Alpine Acquisition	Apr. 10	DJ
Sector Update: Health Care Stocks Steady Premarket Wednesday	Mar. 20	MT
Vera Therapeutics' 2023 Loss Narrows	Mar. 20	MT
Vera Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 20	CI
North American Morning Briefing : Cautious Start -2-	Jan. 29	DJ
Vera Therapeutics, Inc. Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b Origin Clinical Trial Ole in IgA Nephropathy	Jan. 25	CI
Vera Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Vera Therapeutics Presents Positive Data from Phase 2B Origin Study Showing Resolution of Hematuria in Majority of Patients At the American Society of Nephrology Kidney Week 2023	Nov. 04	CI
Novartis drug candidate scores interim win in rare kidney disease trial	23-10-30	RE
Vera Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Vera Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
VERA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	23-03-28	AQ
Vera Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-28	CI
Vera Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-28	CI
Vera Therapeutics, Inc. Releases 36 Week Interim Analysis of Phase 2b Clinical Trial of Atacicept for the Treatment of IgA Nephropathy	23-01-30	CI
Vera Therapeutics, Inc. Hosting A Key Opinion Leader Webinar on Atacicept for the Treatment Iga Nephropathy	23-01-25	CI
Vera Therapeutics, Inc. Announces Positive Topline Results of Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA Nephropathy	23-01-03	CI
VERA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	22-11-09	AQ
Vera Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-09	CI
VERA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	22-08-10	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Vera Therapeutics, Inc.

Equities

VERA

US92337R1014

Highlights

Filters